In addition, further analysis showed that nobiletin inhibited the development of NSCLC through targets such as TP53, CXCL8, ESR1, PPAR-α, and MMP9 and related signaling pathways. This evidence concerns the gene CXCL8 and non-small cell lung carcinoma.